Novo Nordisk $NVO promised blockbuster weight loss from its new drug CagriSema—touting 25% results. But when final trial data landed at 22.7%, investors were stunned. In this episode of Bulls & Betrayal, Anna and Nate dig into the class action lawsuit accusing Novo of misleading shareholders about trial design and results. Perfect for biotech investors, legal watchers, and pharma skeptics, this episode exposes the risks behind drug hype.

Add our WhatsApp Channel.

Visit ZLK.com for more info.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.